AUTHOR=Xie Pan , Liu Jun-Yan , Yan Han , Wang Zhi-Bin , Jiang Shi-Long , Li Xi , Liu Zhao-Qian 

TITLE=Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.950831

DOI=10.3389/fphar.2022.950831

ISSN=1663-9812

ABSTRACT=<p>Discoidin, CUB, and LCCL domain-containing protein 2 (<italic>DCBLD2</italic>) is a two-domain transmembrane protein-coding gene located on chromosome 3, the protein expressed by which acts as the membrane receptor of semaphorin and vascular endothelial growth factor during the development of axons and blood vessels. Although several research evidences at the cellular and clinical levels have associated DCBLD2 with tumorigenesis, nothing is known regarding this gene from a pan-cancer standpoint. In this study, we systematically analyzed the influence of DCBLD2 on prognosis, cancer staging, immune characteristics, and drug sensitivity in a variety of cancers based on a unified and standardized pan-cancer dataset. In addition, we performed GO enrichment analyses and KEGG analyses of <italic>DCBLD2</italic>-related genes and DCBLD2-binding proteins. Our results showed that DCBLD2 is a potential oncogenic, immunological as well as a prognostic biomarker in terms of pan-cancer, and is expected to contribute to the improvement of tumor prognosis and the development of targeted therapy.</p>